MCHM reports Phase III ED data

MacroChem (MCHM) announced after market close on Wednesday that preliminary data from a Phase III erectile dysfunction trial showed its Topiglan did not show statistical significance in patients' ability to maintain an erection to completion of intercourse. The company said this benchmark is typically required for approval of an ED compound. ...